Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.

Hunt T, Kaplan N, Hafkin B.

J Chemother. 2016 Jun;28(3):164-71. doi: 10.1179/1973947815Y.0000000075. Epub 2016 May 13.

PMID:
26431470
2.

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

Kaplan N, Garner C, Hafkin B.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):440-6. doi: 10.1016/j.ejps.2013.08.019. Epub 2013 Aug 27. Erratum in: Eur J Pharm Sci. 2014 Feb 14;52:223.

PMID:
23988847
3.

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.

Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW, Hafkin B.

J Chemother. 2013 Feb;25(1):18-25. doi: 10.1179/1973947812Y.0000000063.

4.

Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5865-74. doi: 10.1128/AAC.01411-12. Epub 2012 Sep 4.

5.

Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).

Sampson PB, Picard C, Handerson S, McGrath TE, Domagala M, Leeson A, Romanov V, Awrey DE, Thambipillai D, Bardouniotis E, Kaplan N, Berman JM, Pauls HW.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5355-8. doi: 10.1016/j.bmcl.2009.07.129. Epub 2009 Aug 6.

PMID:
19682901
6.

2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.

Ramnauth J, Surman MD, Sampson PB, Forrest B, Wilson J, Freeman E, Manning DD, Martin F, Toro A, Domagala M, Awrey DE, Bardouniotis E, Kaplan N, Berman J, Pauls HW.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5359-62. doi: 10.1016/j.bmcl.2009.07.094. Epub 2009 Jul 23.

PMID:
19682900
7.

Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system.

Gao M, Brufatto N, Chen T, Murley LL, Thalakada R, Domagala M, Beattie B, Mamelak D, Athanasopoulos V, Johnson D, McFadden G, Burks C, Frappier L.

J Proteome Res. 2005 Nov-Dec;4(6):2225-35.

PMID:
16335970
8.

The structure of (3R)-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Pseudomonas aeruginosa.

Kimber MS, Martin F, Lu Y, Houston S, Vedadi M, Dharamsi A, Fiebig KM, Schmid M, Rock CO.

J Biol Chem. 2004 Dec 10;279(50):52593-602. Epub 2004 Sep 14.

9.

Reduced triclosan susceptibility in methicillin-resistant Staphylococcus epidermidis.

Schmid MB, Kaplan N.

Antimicrob Agents Chemother. 2004 Apr;48(4):1397-9.

10.

Data mining crystallization databases: knowledge-based approaches to optimize protein crystal screens.

Kimber MS, Vallee F, Houston S, Necakov A, Skarina T, Evdokimova E, Beasley S, Christendat D, Savchenko A, Arrowsmith CH, Vedadi M, Gerstein M, Edwards AM.

Proteins. 2003 Jun 1;51(4):562-8.

PMID:
12784215
11.

High-throughput protein crystallization.

Hui R, Edwards A.

J Struct Biol. 2003 Apr;142(1):154-61. Review.

PMID:
12718927
12.

Structural proteomics: the potential of high-throughput structure determination.

Schmid MB.

Trends Microbiol. 2002;10(10 Suppl):S27-31. Review.

PMID:
12377565

Supplemental Content

Loading ...
Support Center